ライフサイエンスコーパス: every

1 For every 1 point increase in the hospital-level mean score

2 For every 1,000 patients in surveillance over 5 years, there

3 For every 1,000 patients, 150 (95% CI, 146-154) had one or m

4 At 6 mo, every 1-unit increase in the food-insecurity score was a

5 embers were genotyped with markers spaced by every 10 cM and a model-free nonparametric linkage (NPL-

6 tographed the scattered flour for 60 seconds every 10 seconds after sieving through three types of fl

7 ined 4.6% per degrees C, and declined 2% for every 10% decrease in rainfall (for nonirrigated sites).

8 Likewise, for every 10% increase in partial bundle compliance, patient

9 an infection density of 1.19 infections for every 100 days at risk.

10 In fully-adjusted analyses, every 100 mg increase in intake of magnesium was associa

11 psids package one full-length RNA genome for every 11 icosahedral assemblies, similar to the best rec

12 m from morphine-treated (1 or 10 mg/kg, i.p. every 12 h) or saline-treated mice was collected at diff

13 Before, at the end of shock and every 12 hours of resuscitation, datasets comprising hem

14 ceive 200 mg lumacaftor and 250 mg ivacaftor every 12 hours or placebo for 24 weeks.

15 peracillin plasma concentration was measured every 12 hours over a 7-day period by high-pressure liqu

16 verse event compared with 189 (93.5%) in the every 12 weeks group.

17 .50) events per year in the every 4 weeks vs every 12 weeks groups (P = .85).

18 The safety profiles of the every 4 weeks and every 12 weeks groups were comparable, with 189 patients

19 inetic data suggest that 800 mg administered every 12 weeks is a suboptimal regimen; alternative dosi

20 The every 12 weeks regimen of zoledronic acid was noninferio

21 Survival was assessed every 12 weeks, and final analysis occurred after all pa

22 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus

23 Lipids, safety, and tolerability every 12 weeks.

24 dosing group and 253 patients (28.6%) in the every 12-week dosing group experienced at least 1 skelet

25 12.8 months (IQR 9.3-15.5) in the ipilimumab every-12-weeks cohort and 11.8 months (6.7-15.9) in the

26 urred in 14 (37%) patients in the ipilimumab every-12-weeks cohort and 13 (33%) patients in the every

27 % [95% CI 31-64]) patients in the ipilimumab every-12-weeks cohort and 15 (38% [95% CI 23-55]) patien

28 iscontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients in the eve

29 lly received treatment (38 in the ipilimumab every-12-weeks cohort; 39 in the ipilimumab every-6-week

30 ed at stereotyped intervals, both spatially (every 137 degrees in a pattern called phyllotaxis) and t

31 ambulatory blood pressure (BP) was measured every 15 minutes during the working day.

32 Every 2 kg/m(2) increase in BMI above 20 kg/m(2) was ass

33 of deployment in the system vibrated briefly every 2 min, while none of the congeners achieved more t

34 uare meter of body-surface area administered every 2 months for 3 years after transplantation would p

35 easured at enrollment, and eGFR was measured every 2 months in the ESCAPE Trial and every 6 months in

36 Information and blood samples were collected every 2 months.

37 mg of bococizumab or placebo subcutaneously every 2 weeks and who were followed for up to 12 months;

38 nd immunological analysis, we chose 10 mg/kg every 2 weeks as the dose for further development and ph

39 Tension observer and self-ratings completed every 2 weeks during clinic visits.

40 infusion of 7.5 mg/kg MABp1 or placebo given every 2 weeks for 8 weeks.

41 nts were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months.

42 nfections, all in patients in the ixekizumab every 2 weeks group, were reported.

43 Durvalumab was administered at 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks with either olap

44 cizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo.

45 mab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or

46 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks unti

47 response system to receive nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, niv

48 of Health, and meetings with the study team every 2 weeks thereafter, for the duration of the circum

49 to escalating cohorts of 5 patients treated every 2 weeks x 4 doses with a 4-week dose-limiting toxi

50 g daily) and subcutaneous evolocumab (420 mg every 2 weeks) for 8 weeks on the plasma kinetics of ver

51 ; and 207 [71%] of 292 with 100 mg sirukumab every 2 weeks).

52 ice or web response system to either placebo every 2 weeks, 50 mg sirukumab every 4 weeks, or 100 mg

53 sirukumab every 4 weeks, or 100 mg sirukumab every 2 weeks, all given for 52 weeks or less.

54 Patients received 5 mg/kg belatacept every 2 weeks, and the dosing interval was extended to 4

55 consecutive cycles of R-CHOP delivered once every 2 weeks, followed or not by RT at 40 Gy delivered

56 ed 28-day cycles of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, and

57 umab was given as a 1-h intravenous infusion every 2 weeks.

58 ght) or placebo, administered subcutaneously every 2 weeks.

59 osphates (rNTPs) into DNA approximately once every 2,000 base pairs synthesized.

60 of hot-dry summers from once-in-a-decade to every 2-3 years.

61 ery 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-alpha-2b three t

62 igned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21

63 2 years, having seven or more hot flushes in every 24 h of which some were reported as being severe o

64 CT scans were obtained every 24 h throughout dosing.

65 fected nymphal ticks by measuring metabolism every 24 hours over the course of their up to 96 hour bl

66 intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at least 120 weeks and until a prespe

67 intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a d

68 avenously on days 1, 8, and 15, and repeated every 28 days over the 12-week period.

69 ng-acting pasireotide (60 mg intramuscularly every 28 days), everolimus (10 mg orally once daily), or

70 Universities Osteoarthritis index collected every 3 months (Likert pain subscale range, 0 [no pain]

71 and biological sampling and risk assessment every 3 months during participation in a 48-96 week life

72 rs from all inhabitants at baseline and then every 3 months thereafter, for up to 18 months, for anal

73 The participants (n = 140) were followed every 3 months through HBsAg quantification.

74 Conclusion ZA every 3 months was more CE in reducing the risks of SRE

75 nce 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing

76 s (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo.

77 Infestation was assessed every 3 months, and if infestation persisted or recurred

78 son, but saves US$204 compared to monitoring every 3 months.

79 RPR titers were monitored every 3 months.

80 150 mg, or 300 mg) given subcutaneously once every 3 months.

81 ystem to receive either pembrolizumab 200 mg every 3 weeks (35 cycles) or investigator-choice platinu

82 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 weeks (DC) or three cycles of epirubicin (90 mg/

83 en plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks

84 Results PEM every 3 weeks followed by second-line IPI was both more

85 oplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles followed by maintenance pe

86 2 mg/kg plus intravenous ipilimumab 1 mg/kg every 3 weeks for four doses, followed by intravenous pe

87 ollowed by intravenous pembrolizumab 2 mg/kg every 3 weeks for up to 2 years or disease progression,

88 gned (2:1) to ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses.

89 PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transformed CLL.

90 alpituzumab tesirine (0.2 mg/kg or 0.4 mg/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/kg every 6 weeks),

91 ) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable

92 Patients received six cycles (every 3 weeks) of neoadjuvant trastuzumab emtansine plus

93 mpared with cisplatin 100 mg/m(2) given once every 3 weeks, both administered concurrently with curat

94 s of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerable

95 6.0 mg/kg (adjusted ideal body weight) once every 3 weeks.

96 reated with 200 mg intravenous pembrolizumab every 3 weeks.

97 m(2), or 75 mg/m(2) docetaxel) intravenously every 3 weeks.

98 Ipilimumab (3 mg/kg every 3 weeks; up to four doses) began week 1 in the ipi

99 during multiple examinations (approximately every 3 years for up to 27 years).

100 graphy every 5 years, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10

101 Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard

102 39.5 months and was not reached in the once-every-3-weeks arm (HR, 1.14 [95% CI, 0.79 to 1.65]; P =

103 in the once-a-week arm and 73.1% in the once-every-3-weeks arm, leading to an absolute difference of

104 re, and heart rate variability were assessed every 30 min and corrected QT intervals and T-wave morph

105 scores, and plasma parameters were repeated every 30 min during a 150-min period.

106 Perioperative MACCE occurs in 1 of every 33 hospitalizations for noncardiac surgery.

107 orally gavaged with TCDD (0.01-30 microg/kg) every 4 days for 28 days exhibited bile duct proliferati

108 ollowed with at least a clinical examination every 4 mo for 2 y and every 6 mo thereafter.

109 ttent treatment (IN) group with LED for 5 wk every 4 mo for 3 y or to daily meal replacements of 1-2

110 view at 2 years, with prospective collection every 4 months thereafter, until 5 years postacute respi

111 Patient 1 was followed routinely every 4 months while on systemic sunitinib prescribed by

112 United Kingdom and underwent ROCA screening every 4 months.

113 Prostate-specific antigen testing every 4 to 6 months is reasonable for men without metast

114 ntravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 mont

115 nts were re-randomized to receive belatacept every 4 weeks (4-weekly, n = 62) or every 8 weeks (8-wee

116 /kg opicinumab intravenously or placebo once every 4 weeks (six doses) and followed up to week 32.

117 The safety profiles of the every 4 weeks and every 12 weeks groups were comparable,

118 ranibizumab at baseline and as frequently as every 4 weeks based on a structured retreatment protocol

119 ous placebo or benralizumab 30 mg injections every 4 weeks for 12 weeks.

120 ab 100 mg or placebo, plus standard of care, every 4 weeks for 24 weeks (the final dose was given at

121 comparable, with 189 patients (95.5%) in the every 4 weeks group having at least 1 adverse event comp

122 en of zoledronic acid was noninferior to the every 4 weeks regimen for the proportion of patients exp

123 cizumab, 1.25 mg; ranibizumab, 0.3 mg, up to every 4 weeks through 2 years following a retreatment pr

124 32) or 24 weeks (n = 9), and were evaluated every 4 weeks until week 24 and at week 36.

125 (1.06) vs 0.50 (1.50) events per year in the every 4 weeks vs every 12 weeks groups (P = .85).

126 stered at 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks with either olaparib tablets twice daily o

127 ither placebo every 2 weeks, 50 mg sirukumab every 4 weeks, or 100 mg sirukumab every 2 weeks, all gi

128 Every 4 weeks, participants underwent best-corrected vis

129 mg, or aflibercept, 2.0 mg, at baseline and every 4 weeks, with the primary outcome measured at 6 mo

130 nts administered belatacept every 8 weeks vs every 4 weeks.

131 f 294; 194 [66%] of 292 with 50 mg sirukumab every 4 weeks; and 207 [71%] of 292 with 100 mg sirukuma

132 y questionnaires at baseline and was updated every 4 years.

133 requency questionnaire (FFQ) at baseline and every 4 years.

134 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patients (28.6%) in th

135 s into CD40(-/-)apoE(-/-) mice was performed every 5 days, starting at 2 days before wire injury.

136 st every 3 years, and flexible sigmoidoscopy every 5 to 10 years.

137 urrent obstacles to use, capsule colonoscopy every 5 years is a third-tier test.

138 ommended to undergo screening by colonoscopy every 5 years, beginning 10 years before the age at diag

139 Colonoscopy every 5 years, starting at age 40 years, was the optimal

140 Colonoscopy every 5 years, starting at an age of 40 years, was the o

141 he second-tier tests include CT colonography every 5 years, the FIT-fecal DNA test every 3 years, and

142 r instance, HSP101 abundance declined 2-fold every 5.1 min.

143 clinical examination every 4 mo for 2 y and every 6 mo thereafter.

144 troke) and all-cause mortality were reported every 6 months and confirmed by medical record adjudicat

145 d rapid HIV testing during home-based visits every 6 months for about 4 years in four clusters, 3 yea

146 ment were followed with HCV RNA measurements every 6 months in a prospective cohort study.

147 sured every 2 months in the ESCAPE Trial and every 6 months in the 4C Study.

148 Serum samples obtained every 6 months were evaluated for seroconversion, define

149 th more than 4 semi-annual follow-up visits (every 6 months) in the multicenter Advanced Imaging for

150 nts) and underwent an ultrasound examination every 6 months, as well as endoscopic evaluations.

151 nes empirically recommend serial evaluations every 6 to 12 months.

152 Imaging was performed every 6 to 9 weeks.

153 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable to

154 g/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/kg every 6 weeks), 11 (18%) of 60 assessable patients had a

155 Every 6 weeks, 1 hospital was randomly assigned to switc

156 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipil

157 One patient in the ipilimumab every-6-weeks cohort was excluded before treatment; ther

158 every-12-weeks cohort; 39 in the ipilimumab every-6-weeks cohort).

159 and 11.8 months (6.7-15.9) in the ipilimumab every-6-weeks cohort.

160 -weeks cohort and five (13%) patients in the every-6-weeks cohort.

161 % [95% CI 23-55]) patients in the ipilimumab every-6-weeks cohort; median duration of response was no

162 12-weeks cohort and 13 (33%) patients in the every-6-weeks cohort; the most commonly reported grade 3

163 corrected QT intervals and T-wave morphology every 60 min.

164 This is essential, considering that 1 in every 600 Caucasian children is IgA deficient.

165 ning a program for 17h that turned on an LED every 60s.

166 Using this technique, we found that every 70 mL puff of an e-cigarette deposited 0.019% e-li

167 , or approximately 1 extra breast cancer for every 7690 women using hormonal contraception for 1 year

168 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens were adjusted for ren

169 00 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by 30-min intravenous i

170 latacept every 4 weeks (4-weekly, n = 62) or every 8 weeks (8-weekly, n = 60).

171 ion (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular la

172 th intravitreal aflibercept injection (2 mg) every 8 weeks after 5 monthly doses with sham injections

173 d higher in patients administered belatacept every 8 weeks vs every 4 weeks.

174 received three 10 or 30 mg/kg IV VRC01 doses every 8 weeks, respectively.

175 Every additional day without a weaning success after the

176 For every additional species consumed, dietary nutrient adeq

177 h an average of 12.09 weeks +/- 2.16 between every administration.

178 Every alignment algorithm consists of two orthogonal com

179 ane-to-nucleus signaling module that affects every aspect of the mammalian immune system.

180 vealed roles for mRNA modification in nearly every aspect of the mRNA life cycle, as well as in vario

181 ling technological advances affecting nearly every aspect of this field: from lead discovery, to synt

182 CSR creates a virtually unique IgH locus in every B cell clone by intrachromosomal recombination bet

183 Here, we compile folding information for every base pair of the genome that may be transcribed: c

184 hey do not have sufficient electrons to give every bond an electron pair.

185 bonds between two aromatic rings has enabled every branch of chemical science.

186 c arrest database (which contains records of every cardiac arrest attended by paramedics in the netwo

187 ive to cisplatin and etoposide but in almost every case becomes rapidly chemoresistant, leading to de

188 We aimed to enrol four controls for every case not infected with HIV and six controls for ev

189 e not infected with HIV and six controls for every case with HIV infection (case-control sets).

190 Nearly every cell in the human body contains a set of programma

191 n is a fundamental step in the life cycle of every cell.

192 nome integrity with distinct roles in almost every cellular process requiring access to DNA.

193 papillomavirus (HPV) infections cause nearly every cervical carcinoma and a subset of tumors in the o

194 two mechanistic modes of chain collapse for every chain constituting the SCNP sample.

195 dominate the concentration levels of TEX in every city despite the reduction of their emissions at e

196 resentations and processes without "proving" every component.

197 Additionally, for every compound tested, activity was dependent on the pre

198 tage over men is likely to shrink by 2030 in every country except Mexico, where female life expectanc

199 , creative, and motivated-and that come from every country in the world.

200 ated global incidence by aggregating up from every country, using a survey for the year in question w

201 Microbes are present at every crime scene and have been used as physical evidenc

202 , predicts pediatric falls when administered every day and night shift, but identifies most patients

203 c intakes occur consistently within </= 12 h every day exerts many cardiometabolic benefits.

204 that nearly 1 million people become infected every day with any of four curable sexually transmitted

205 sive associated health effects across nearly every dimension of human health.

206 ondria, the ubiquitous power packs in nearly every eukaryotic cell, contain their own DNA, known as m

207 We propose that this effort is updated every few years to include the most recently published e

208 In every fuel tested, dinitrogen pentoxide (N2O5) formed qu

209 -level probabilities of loss of function for every gene across all strains.

210 a and unambiguously shows the correlation of every Greenland interstadial identified in isotope recor

211 Surgery is offered for almost every heart defect, despite complexity.

212 s a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA, Group 1) or qid (Group 2)

213 ed the standard of care with IS use 10 times every hour while awake.

214 ere decreases in proportion seropositive for every HPV type across all age groups, many statistically

215 To date every identified ArsR is regulated by inorganic As(III).

216 Nearly every important control on marine microbial physiology i

217 A prospective nationwide cohort study of every infant requiring surgical intervention for NEC in

218 em to protect an otherwise healthy host from every infection that could threaten its life.

219 odifier, ubiquitin (Ub), regulates virtually every known cellular process in eukaryotes.

220 cations in Galphai that preclude coupling to every known major binding partner [GPCRs, Gbetagamma, ef

221 Similar pathological changes also occur at every level of the spinal cord of PPT1-deficient (Ppt1(-

222 nism intended to facilitate extensibility at every level, with the goal of creating a more powerful t

223 sistently by all other dental specialties in every measured metric on the Yelp website.

224 med Medical Law and Professional Studies, at every medical school.

225 Although not every minor methylation differences between cells are de

226 00 PKR; the cash or voucher amount was given every month over six consecutive months.

227 Like every motor action, these eye movements are subject to n

228 individual and pairwise epistatic effects of every mutation to our model protein-and then used this i

229 it would be ideal to record the activity of every neuron in a behaving animal and decode how it rela

230 library in strain AB5075 with insertions in every nonessential gene was subjected to selection in NH

231 Every one point increase in sum score at discharge was a

232 cess, which has been seen to occur typically every one to three years since the 1980s.

233 to test sites immediately after surgery and every other day for 14 days (total of eight applications

234 ) was administered at the onset of diabetes, every other day for 4 weeks (paradigm B).

235 imab given in 2 schedules (3, 5, or 10 mg/kg every other week [Q2W] or 10 or 20 mg/kg weekly [QW] for

236 or 0.4 mg/kg subcutaneously at week 0, then every other week starting at week 1, or oral methotrexat

237 those in the group that received tocilizumab every other week, 22% of those in the placebo group that

238 adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to b

239 tocilizumab (at a dose of 162 mg) weekly or every other week, combined with a 26-week prednisone tap

240 consuming, I have become quite familiar with every paper that we publish.

241 Every participant was randomly assigned to 1 of 3 equiva

242 C(+) NK cell expansions were not observed in every patient with detectable viremia who received preem

243 Human astroviruses (HAstVs) infect nearly every person in the world during childhood and cause dia

244 ferent modifications have been described and every position in the purine and pyrimidine bases can be

245 imuli when an immediate reward was given for every predictive movement.

246 natal dose, but revaccinating mothers during every pregnancy decreased incidence for these infants by

247 enior general surgeon (SGS) is obligatory in every procedure, including appendectomy, while in others

248 the access and deep drug binding pockets in every protomer.

249 s the long-standing open question of whether every pure bipartite entangled state is self-testable.

250 HPLC/ELSD method does not require each and every pure standard of saponins, to quantify the group o

251 Every quintile increment in BW/GA percentile was associa

252 TARTs have a typical imaging appearance that every radiologist must be aware of.

253 sents a set of good computing practices that every researcher can adopt, regardless of their current

254 ed outcomes were measured at baseline and at every restaging visit by using the MD Anderson Symptoms

255 ments that we make approximately three times every second to scan the visual scene for interesting th

256 nosystem can capture massive amounts of data every second, store it directly on-chip, perform in situ

257 By resolving every single pMHC:TCR interaction it is evident that thi

258 ions, such as perceiving a forest instead of every single tree.

259 to map the complete glycosylation profile at every site in multiple HIV-1 Env trimers, accomplishing

260 se to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response

261 while tapping creativity and expertise from every source.

262 ntial to affect the ecology and evolution of every species on Earth.

263 tion through vaccination requires preventing every sporozoite inoculated by mosquito bite: a major ch

264 on and 100% recall and accurately identifies every SSR of any specified length.

265 n to regulate gene expression at practically every stage, ranging from chromatin packaging to mRNA tr

266 they can more closely control and monitor at every stage.

267 ein diversification mechanisms that exist at every step of the protein biosynthesis pathway, such as

268 The present study reveals that every step of this coupling is mediated by a single mole

269 ng, humans need to adapt these parameters at every step to respond to exogenous and/or endogenic pert

270 s, genome-wide sequence and variant data for every strain, and a GWA mapping portal for studying natu

271 measurement platform and repeatedly sampled every street in a 30-km(2) area of Oakland, CA, developi

272 major white matter tracts were extracted for every subject.

273 ionary diversity (there are yeast species in every subphylum of Dikarya) sparked curiosity but necess

274 re consistently differentially methylated in every subtype and all implicated genes are localized to

275 Every supernova so far observed has been considered to b

276 ary layers indicate the start of a new cycle every time with respect to the calculations of diffusion

277 en subsequent doses were increased 1.5 times every time.

278 llitus is a complex disease affecting almost every tissue and organ system, with metabolic complicati

279 It will require every tool in our store of methods to properly understan

280 ween a gamble and a safe (certain) option on every trial.

281 ichiometry of one Delta22-monomer binding to every two consecutive GGAA-repeats on shorter microsatel

282 s in the 500 color channels of LINCS L1000, every two landmark genes are designed to share a single

283 Every two months the UNDERPIN-ICU program will be implem

284 Approximately one in every two patients with pharmacoresistant temporal lobe

285 However, not every virus-antibody combination results in complete neu

286 Each patient then had every visit for 2 years reviewed twice, once for billing

287 ); 2 had undetectable drug concentrations at every visit, 2 had low concentrations at the seroconvers

288 with clinical examination and keratometry at every visit.

289 Staff masked to allocation made home visits every week from enrolment to 6 months after delivery.

290 d by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and dai

291 d that Myc is required for the expression of every Wnt9b/beta-catenin progenitor renewal target asses

292 avivirus responsible for thousands of deaths every year for which there are no specific anti-virals.

293 Millions of people die every year from diseases caused by exposure to outdoor a

294 ever, Latinos had a higher DR probability at every year of duration of T2DM (>/= 5 years).

295 Every year pharmaceutical companies use significant reso

296 elevant number of fatal cases (about 20,000) every year worldwide.

297 nal influenza vaccine formulas change almost every year yet information about how this affects the an

298 (versus 0.1% expected), whereas at any age, every year, 0.2% of head and neck tumor survivors were h

299 Beyond 60 years of age, every year, 0.4% of CNS tumor survivors were hospitalize

300 Every year, Ramadan fasting is practiced by many Muslim

301 and US$3.5 billion of economic productivity every year, which is comparable to recent acute epidemic

302 ns equivalent to their deadly 2015 heatwaves every year.

303 mplex, with several hundred new publications every year.

304 o-borne disease affecting millions of people every year.

305 ection costs hundreds of millions of dollars every year.